Related references
Note: Only part of the references are listed.Effects of Belapectin, an Inhibitor of Galectin-3, in Patients With Nonalcoholic Steatohepatitis With Cirrhosis and Portal Hypertension
Naga Chalasani et al.
GASTROENTEROLOGY (2020)
The Natural History of Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: Data From the Simtuzumab Trials
Arun J. Sanyal et al.
HEPATOLOGY (2019)
Non-invasive assessment of non-alcoholic fatty liver disease: Clinical prediction rules and blood-based biomarkers
Eduardo Vilar-Gomez et al.
JOURNAL OF HEPATOLOGY (2018)
Noninvasive Assessment of Portal Hypertension in Advanced Chronic Liver Disease: An Update
Federico Ravaioli et al.
GASTROENTEROLOGY RESEARCH AND PRACTICE (2018)
Enhanced liver fibrosis test as a reliable tool for assessing fibrosis in nonalcoholic fatty liver disease in a clinical setting
Luca Miele et al.
INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS (2017)
Cirrhosis and portal hypertension: The importance of risk stratification, the role of hepatic venous pressure gradient measurement
Vincenzo La Mura et al.
WORLD JOURNAL OF HEPATOLOGY (2015)
The clinical use of HVPG measurements in chronic liver disease
Jaime Bosch et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2009)
Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European liver fibrosis panel and exploring simple markers
Indra Neil Guha et al.
HEPATOLOGY (2008)
Share Paper
